The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene under study is confirmed as FGF19 (Fibroblast Growth Factor 19), UniProt accession O95750, in Homo sapiens. This gene encodes a 216-amino-acid secretory protein belonging to the heparin-binding growth factors family, specifically the FGF19 subfamily of endocrine fibroblast growth factors (xu2026fgf19insolid pages 6-7, sadowska2023theroleof pages 2-4). FGF19 is the human ortholog of mouse FGF15 (katafuchi2022molecularbasisof pages 8-10, ciaula2022recentadvancesin pages 5-6). The protein domains include FGF15/19/21 (IPR035444), Fibroblast_GF_fam (IPR002209), and the FGF domain (PF00167), consistent with the UniProt annotation.
FGF19 functions primarily as an endocrine metabolic regulator rather than a classical paracrine growth factor (carvalho2024theroleof pages 5-8, li2024targetingthefgf19–fgfr4 pages 2-3). Unlike conventional fibroblast growth factors, FGF19 has limited affinity for extracellular heparan sulfate proteoglycans, which enables it to enter systemic circulation and act as a circulating hormone at distant target tissues (carvalho2024theroleof pages 1-5). This endocrine function distinguishes FGF19 from paracrine FGFs and places it within the atypical FGF19 subfamily alongside FGF21 and FGF23 (henriksson2020fgf19andfgf21 pages 3-5, ciaula2022recentadvancesin pages 5-6).
The most well-established primary function of FGF19 is regulation of bile acid synthesis through negative feedback in the enterohepatic circulation (li2024targetingthefgf19–fgfr4 pages 2-3, li2024targetingthefgf19–fgfr4 pages 2-2). Following postprandial bile acid absorption in the distal ileum, bile acids activate the nuclear receptor Farnesoid X Receptor (FXR), which forms a heterodimer with RXRα and binds to FXR response elements in the FGF19 gene, inducing its transcription (katafuchi2022molecularbasisof pages 8-10, katafuchi2022molecularbasisof pages 10-11). The secreted FGF19 enters the portal circulation and travels to hepatocytes, where it binds to a receptor complex consisting of Fibroblast Growth Factor Receptor 4 (FGFR4) and its obligate co-receptor beta-Klotho (KLB) (wang2022theroleof pages 3-4, li2024targetingthefgf19–fgfr4 pages 2-2).
Activation of the hepatic FGFR4-KLB complex triggers intracellular signaling pathways, including ERK1/2 and JNK activation, which lead to transcriptional suppression of CYP7A1 (cholesterol 7α-hydroxylase), the rate-limiting enzyme in the classical pathway of bile acid synthesis from cholesterol (simbrunner2021reviewarticletherapeutic pages 5-6, li2024targetingthefgf19–fgfr4 pages 2-3). This suppression can occur through both SHP-dependent and SHP-independent mechanisms: the nuclear corepressor SHP (small heterodimer partner) inhibits the transcriptional activity of HNF4α and LRH-1, thereby repressing CYP7A1 expression (katafuchi2022molecularbasisof pages 8-10, xu2026fgf19insolid pages 6-7). Additionally, FGF19 signaling can directly suppress CYP7A1 through JNK and mTOR/ERK-mediated pathways (katafuchi2022molecularbasisof pages 11-13). This negative feedback mechanism maintains bile acid pool homeostasis and prevents excessive bile acid accumulation (ciaula2022recentadvancesin pages 5-6).
FGF19 is synthesized primarily in ileal enterocytes of the small intestine, particularly the distal ileum, in response to bile acid-mediated FXR activation (katafuchi2022molecularbasisof pages 8-10, carvalho2024theroleof pages 1-5, li2024targetingthefgf19–fgfr4 pages 2-2). Additional expression has been reported in the gallbladder, kidney, skin, cartilage, brain, adipose tissue, and pancreas, though the intestine remains the predominant physiological source of circulating FGF19 (sadowska2023theroleof pages 2-4, ciaula2022recentadvancesin pages 5-6, xu2026fgf19insolid pages 6-7).
Notably, FGF19 lacks a conventional signal peptide and does not follow the standard endoplasmic reticulum-Golgi secretory pathway (xu2026fgf19insolid pages 6-7). Alternative secretion mechanisms have been proposed, including secretory lysosomes and direct translocation across the cell membrane (xu2026fgf19insolid pages 6-7). Following secretion, FGF19 enters the systemic circulation and functions as an endocrine hormone (carvalho2024theroleof pages 5-8).
As a circulating hormone, FGF19 acts primarily on hepatocytes in the liver, where FGFR4 and KLB are highly co-expressed (henriksson2020fgf19andfgf21 pages 3-5, ciaula2022recentadvancesin pages 5-6, li2024targetingthefgf19–fgfr4 pages 2-2). Secondary target tissues include:
FGF19 signals through fibroblast growth factor receptors (FGFRs) in conjunction with the transmembrane co-receptor beta-Klotho (KLB) (sadowska2023theroleof pages 2-4, carvalho2024theroleof pages 1-5). The receptor specificity is as follows:
The FGF19 protein binds to the extracellular immunoglobulin-like domains D2 and D3 of FGFR4, forming a stable high-affinity complex that does not require heparan sulfate, unlike canonical FGFs (xu2026fgf19insolid pages 6-7). The complete signaling complex consists of FGF19, FGFR4, KLB, and heparan sulfate in a 1:1:1:1 stoichiometry (katafuchi2022molecularbasisof pages 10-11). FGF19's C-terminal tail binds to KLB, while its N-terminal region interacts with the FGFR (park2022isoformspecificinhibitionof pages 10-11).
Upon FGF19 binding, the FGFR undergoes conformational changes, dimerization, and autophosphorylation of cytoplasmic tyrosine residues, creating docking sites for downstream signaling proteins (xu2026fgf19insolid pages 6-7, carvalho2024theroleof pages 1-5). Key activated pathways include:
Importantly, different signaling outputs can be distinguished by receptor-complex assembly strength: strong dimerization supports mitogenic ERK1/2 signaling, while bile acid feedback (CYP7A1 repression) can occur without extensive receptor dimerization (katafuchi2022molecularbasisof pages 10-11).
FGF19 has insulin-independent glucose-lowering effects through multiple mechanisms (ciaula2022recentadvancesin pages 8-9, carvalho2024theroleof pages 5-8):
Hepatic Glycogen Synthesis: FGF19 promotes glycogen storage through the ERK-p90RSK pathway, which phosphorylates and inactivates glycogen synthase kinase-3α/β (GSK3α/β) (sadowska2023theroleof pages 2-4, wang2022theroleof pages 3-4). Inactivation of GSK3 relieves its inhibitory effect on glycogen synthase, thereby enhancing glycogen formation. Acute FGF19 treatment increased hepatic glycogen synthase activity and glycogen content by approximately 30%, and FGF19 restored reduced glycogen stores in Fgf15-knockout and insulin-deficient diabetic mice, demonstrating an insulin-independent mechanism (carvalho2024theroleof pages 5-8).
Suppression of Gluconeogenesis: FGF19 inhibits hepatic glucose production by promoting dephosphorylation and inactivation of CREB (cAMP response element-binding protein), which reduces expression of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and downstream gluconeogenic genes including glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PCK1/PEPCK) (ciaula2022recentadvancesin pages 8-9, carvalho2024theroleof pages 5-8, sadowska2023theroleof pages 2-4). This CREB-PGC-1α pathway suppression occurs independently of insulin and AKT signaling (ciaula2022recentadvancesin pages 8-9).
FGF19 influences lipid metabolism across multiple tissues (li2024targetingthefgf19–fgfr4 pages 2-2, carvalho2024theroleof pages 8-11):
Hepatic Lipogenesis: FGF19 inhibits de novo lipogenesis through activation of STAT3, reduction of PGC-1β and SREBP-1c signaling, and induction of SHP (carvalho2024theroleof pages 8-11, carvalho2024theroleof pages 5-8). This leads to decreased expression of lipogenic enzymes including fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), acetyl-CoA carboxylase 2 (ACC2), ACSL3, and FABP5. FGF19 treatment reduces hepatic triglyceride and free fatty acid content in preclinical models (carvalho2024theroleof pages 8-11).
Fatty Acid Oxidation: FGF19 promotes fatty acid oxidation, evidenced by increased expression of the peroxisomal oxidation enzyme ACOX1 (carvalho2024theroleof pages 8-11). However, effects on β-oxidation can be context-dependent, varying with model systems, doses, and receptor expression patterns (carvalho2024theroleof pages 8-11, carvalho2024theroleof pages 11-14).
Adipose Tissue: FGF19 reduces adiposity and body weight while increasing energy expenditure (carvalho2024theroleof pages 8-11, carvalho2024theroleof pages 11-14). It promotes browning of white adipose tissue, inducing mitochondrial, thermogenic, and fatty acid metabolism genes, including UCP1 in some models (carvalho2024theroleof pages 8-11, carvalho2024theroleof pages 11-14). FGF19 activates FGFR1c-KLB signaling in adipocytes and increases glucose uptake, though adipocyte-specific FGFR1 deletion does not prevent FGF19-mediated glucose lowering in vivo, suggesting indirect mechanisms (carvalho2024theroleof pages 11-14).
FGF19 influences whole-body energy balance through central and peripheral mechanisms. In the central nervous system, FGF19 can engage FGFR1-KLB receptors in the hypothalamus, reducing orexigenic AgRP/NPY neuronal activity and decreasing food intake (sadowska2023theroleof pages 4-5). It also increases energy expenditure through corticotropin-releasing factor and sympathetic nervous system activation, promoting thermogenesis in brown adipose tissue (henriksson2020fgf19andfgf21 pages 6-7). Additionally, by suppressing bile acid synthesis, FGF19 may reduce intestinal lipid digestion and absorption, indirectly contributing to its anti-obesogenic effects (carvalho2024theroleof pages 11-14).
| Function/Process | Mechanism/Pathway | Target Tissue/Receptor | Key Evidence |
|---|---|---|---|
| Bile-acid feedback regulation | Postprandial bile acids activate ileal FXR–RXRα, inducing FGF19 transcription and secretion. Circulating FGF19 activates FGFR4–β-Klotho (KLB) and downstream FRS2–ERK1/2 and JNK signaling to repress CYP7A1; SHP-mediated inhibition of HNF4α/LRH-1 can contribute. | Distal-ileal enterocytes to portal circulation to hepatocyte FGFR4–KLB | Human FGF19 is the endocrine counterpart of rodent FGF15. Loss of FGFR4 or KLB prevents effective FGF19-mediated CYP7A1 repression, supporting this gut–liver axis as its primary homeostatic function. (katafuchi2022molecularbasisof pages 8-10, li2024targetingthefgf19–fgfr4 pages 2-2, katafuchi2022molecularbasisof pages 10-11) |
| Gallbladder filling and enterohepatic coordination | FGF19 promotes gallbladder smooth-muscle relaxation and refilling after bile release, coordinating bile storage with inhibition of new bile-acid synthesis. | Gallbladder FGFR4–KLB | Physiological and experimental evidence identifies gallbladder relaxation as part of the FXR–FGF19 enterohepatic program. (li2024targetingthefgf19–fgfr4 pages 2-2, ciaula2022recentadvancesin pages 5-6) |
| Hepatic glycogen synthesis | FGF19 activates ERK–p90RSK, which phosphorylates and inhibits GSK3α/β. This relieves inhibition of glycogen synthase and increases glycogen formation through a pathway distinct from insulin-mediated PI3K–AKT signaling. | Primarily liver; hepatic FGFR signaling, especially FGFR4–KLB | Acute FGF19 treatment increased hepatic glycogen synthase activity and glycogen content by approximately 30%. FGF19 also restored glycogen in Fgf15-deficient and insulin-deficient diabetic mice, supporting an insulin-independent mechanism. (carvalho2024theroleof pages 5-8, wang2022theroleof pages 3-4) |
| Suppression of hepatic gluconeogenesis | FGF19 promotes dephosphorylation and inactivation of CREB, reducing PGC-1α induction and transcription of gluconeogenic genes including G6PC and PCK1/PEPCK. | Liver; principally FGFR4-associated endocrine signaling | Fgf15 deficiency increases gluconeogenic flux after pyruvate or lactate challenge, whereas FGF15/19 signaling reduces it independently of insulin and AKT. (ciaula2022recentadvancesin pages 8-9, carvalho2024theroleof pages 5-8, sadowska2023theroleof pages 2-4) |
| Hepatic lipogenesis and steatosis | FGF19 can activate STAT3, reduce PGC-1β/SREBP-1c signaling, increase SHP, and decrease lipogenic genes including FASN, SCD1, ACC2, ACSL3, and FABP5. Increased ACOX1 is consistent with enhanced peroxisomal fatty-acid oxidation. | Liver; mainly FGFR4–KLB, with possible indirect FGFR1–KLB inter-organ effects | FGF19 or nonmitogenic analogs reduced hepatic triglycerides, free fatty acids, and steatosis in preclinical models. Lipid-oxidation results vary with model, dose, and receptor context. (carvalho2024theroleof pages 8-11, carvalho2024theroleof pages 5-8) |
| Adipose remodeling and energy expenditure | FGF19 can activate adipocyte FGFR1c–KLB, increase glucose uptake in vitro, and promote white-adipose browning, mitochondrial and thermogenic programs, lipid oxidation, and energy expenditure. Reduced bile-acid synthesis and lipid absorption may also indirectly reduce adiposity. | White and brown adipose tissue; FGFR1c–KLB and context-dependent FGFR signaling | Gain-of-function models show reduced adiposity and body weight with increased energy expenditure; Fgf15 deficiency reduces UCP1 and beige-adipocyte markers. The necessity of brown-fat thermogenesis remains uncertain. (carvalho2024theroleof pages 8-11, carvalho2024theroleof pages 11-14, li2024targetingthefgf19–fgfr4 pages 2-3) |
| Skeletal-muscle metabolism | FGF19 activates AMPK, ERK1/2, mTORC1, and AMPK–SIRT1–PGC-1α programs, supporting mitochondrial function and reducing palmitate-induced lipid-droplet accumulation; effects on β-oxidation are context dependent. | Skeletal muscle; FGFR–KLB complexes | Cell and animal studies support effects on muscle mass, mitochondrial biogenesis, oxidative stress, and lipid handling, but these are less firmly established as human physiological functions. (carvalho2024theroleof pages 11-14) |
| Central control of appetite and energy balance | Circulating FGF19 can engage central FGFR1–KLB, reduce orexigenic AgRP/NPY neuronal activity, and increase energy expenditure through corticotropin-releasing-factor and sympathetic pathways. | Central nervous system and hypothalamus; FGFR1–KLB | Preclinical evidence links central KLB-dependent signaling to reduced food intake, body weight, and hepatic steatosis; its quantitative contribution in humans remains unresolved. (sadowska2023theroleof pages 4-5, henriksson2020fgf19andfgf21 pages 6-7) |
| Mitogenic and regenerative signaling | Strong FGFR4-complex assembly and dimerization activate FRS2–GRB2–RAS–RAF–ERK1/2 and PI3K–AKT, promoting hepatocyte proliferation and regeneration; chronic excessive signaling can be oncogenic. CYP7A1 repression can persist in variants with reduced receptor-dimerization capacity. | Liver and FGF19-driven tumors; FGFR4, enhanced by KLB | Structure–function studies distinguish high-threshold mitogenic signaling from lower-threshold metabolic signaling: weakened FGFR, KLB, or heparan-sulfate interactions reduce proliferation while retaining bile-acid and glycemic actions. (xu2026fgf19insolid pages 6-7, katafuchi2022molecularbasisof pages 10-11, li2024targetingthefgf19–fgfr4 pages 3-3) |
| Receptor selectivity and signal initiation | Weak extracellular-matrix heparan-sulfate affinity permits endocrine circulation. FGF19 activates FGFR1c/2c/3c only with KLB and activates FGFR4 most effectively with KLB. Receptor dimerization and tyrosine autophosphorylation initiate ERK1/2, PI3K–AKT, JNK, STAT3, and mTORC1 signaling. | KLB-expressing liver, adipose tissue, muscle, and CNS; FGFR1c–4 | Tissue-restricted FGFR and KLB co-expression determines responsiveness, helping explain why hepatic FGFR4 primarily controls bile acids while FGFR1c-associated signaling contributes to broader metabolic effects. (carvalho2024theroleof pages 1-5, xu2026fgf19insolid pages 6-7) |
Table: This table summarizes the principal and secondary functions of human FGF19, connecting receptor complexes and downstream pathways to tissue-specific biological outputs. It distinguishes the established FXR–FGF19–FGFR4/KLB bile-acid feedback loop from broader, mainly preclinical metabolic and mitogenic effects.
Recent clinical research (2023-2025) has explored FGF19 as a biomarker and therapeutic target in various metabolic and liver diseases (li2024targetingthefgf19–fgfr4 pages 2-3). FGF19 analogs, particularly aldafermin (NGM282), have shown promise in Phase 2 clinical trials for non-alcoholic steatohepatitis (NASH), primary biliary cholangitis, and primary sclerosing cholangitis, reducing hepatic steatosis by up to 70% (as measured by MRI-PDFF) and improving fibrosis within 12-16 weeks of treatment (henriksson2020fgf19andfgf21 pages 3-5). However, chronic FGF19 administration has mitogenic potential through FGFR4 activation, which has driven development of non-mitogenic FGF19 variants that retain metabolic benefits while reducing tumor-promoting activity (katafuchi2022molecularbasisof pages 10-11, li2024targetingthefgf19–fgfr4 pages 3-3).
FGF19 belongs to the endocrine FGF subfamily that evolved specialized signaling properties through structural adaptations. The weak heparan sulfate affinity results from modifications in the heparin-binding domain, enabling systemic circulation rather than local matrix sequestration (carvalho2024theroleof pages 1-5). The requirement for Klotho co-receptors provides tissue specificity, as FGFR and KLB co-expression patterns determine which cells can respond to circulating FGF19 (carvalho2024theroleof pages 1-5, sun2023thefibroblastgrowth pages 1-2). This endocrine architecture allows intestinal bile acid sensing to coordinate hepatic, adipose, muscle, and central nervous system metabolic responses.
FGF19 (UniProt O95750) is a multifunctional endocrine hormone with a primary, well-established role in bile acid homeostasis through the intestinal FXR-FGF19-hepatic FGFR4/KLB feedback axis. The hormone is synthesized in ileal enterocytes in response to postprandial bile acids and secreted into circulation, where it acts on hepatocytes to suppress CYP7A1 and bile acid synthesis. Beyond this core function, FGF19 regulates glucose metabolism by promoting insulin-independent hepatic glycogen synthesis and suppressing gluconeogenesis, modulates lipid metabolism by inhibiting hepatic lipogenesis and promoting fatty acid oxidation, and influences whole-body energy balance through actions in adipose tissue and the central nervous system. These diverse metabolic functions are mediated through tissue-specific FGFR-KLB receptor complexes and downstream activation of ERK1/2, PI3K-AKT, JNK, STAT3, and mTORC1 pathways. Understanding FGF19 biology has significant therapeutic implications for metabolic diseases, cholestatic liver disorders, and metabolic syndrome.
References
(xu2026fgf19insolid pages 6-7): Jiayi Xu, Peng Sun, Wenjing Zhu, Xinlin Liu, and Lei-Na Ma. Fgf19 in solid tumors: molecular mechanisms, metabolic reprogramming, and emerging therapeutic opportunities. Theranostics, 16:345-397, Jan 2026. URL: https://doi.org/10.7150/thno.121601, doi:10.7150/thno.121601. This article has 6 citations and is from a domain leading peer-reviewed journal.
(sadowska2023theroleof pages 2-4): Agata Sadowska, Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński. The role of the fgf19 family in the pathogenesis of gestational diabetes: a narrative review. International Journal of Molecular Sciences, 24:17298, Dec 2023. URL: https://doi.org/10.3390/ijms242417298, doi:10.3390/ijms242417298. This article has 15 citations.
(katafuchi2022molecularbasisof pages 8-10): Takeshi Katafuchi and Makoto Makishima. Molecular basis of bile acid-fxr-fgf15/19 signaling axis. International Journal of Molecular Sciences, 23:6046, May 2022. URL: https://doi.org/10.3390/ijms23116046, doi:10.3390/ijms23116046. This article has 219 citations.
(ciaula2022recentadvancesin pages 5-6): Agostino Di Ciaula, Leonilde Bonfrate, Jacek Baj, Mohamad Khalil, Gabriella Garruti, Frans Stellaard, Helen H. Wang, David Q.-H. Wang, and Piero Portincasa. Recent advances in the digestive, metabolic and therapeutic effects of farnesoid x receptor and fibroblast growth factor 19: from cholesterol to bile acid signaling. Nutrients, 14:4950, Nov 2022. URL: https://doi.org/10.3390/nu14234950, doi:10.3390/nu14234950. This article has 74 citations.
(carvalho2024theroleof pages 5-8): Marcela Botelho de Carvalho, Gabriel Machado Chavez Passos Jorge, Luiza Wolf Zanardo, Leticia Miho Hamada, Larissa dos Santos Izabel, Sergio Santoro, and Juliana Magdalon. The role of fgf19 in metabolic regulation: insights from preclinical models to clinical trials. Sep 2024. URL: https://doi.org/10.1152/ajpendo.00156.2024, doi:10.1152/ajpendo.00156.2024. This article has 27 citations.
(li2024targetingthefgf19–fgfr4 pages 2-3): Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, and Yongde Luo. Targeting the fgf19–fgfr4 pathway for cholestatic, metabolic, and cancerous diseases. Journal of Internal Medicine, 295:292-312, Jan 2024. URL: https://doi.org/10.1111/joim.13767, doi:10.1111/joim.13767. This article has 66 citations and is from a domain leading peer-reviewed journal.
(carvalho2024theroleof pages 1-5): Marcela Botelho de Carvalho, Gabriel Machado Chavez Passos Jorge, Luiza Wolf Zanardo, Leticia Miho Hamada, Larissa dos Santos Izabel, Sergio Santoro, and Juliana Magdalon. The role of fgf19 in metabolic regulation: insights from preclinical models to clinical trials. Sep 2024. URL: https://doi.org/10.1152/ajpendo.00156.2024, doi:10.1152/ajpendo.00156.2024. This article has 27 citations.
(henriksson2020fgf19andfgf21 pages 3-5): Emma Henriksson and Birgitte Andersen. Fgf19 and fgf21 for the treatment of nash—two sides of the same coin? differential and overlapping effects of fgf19 and fgf21 from mice to human. Frontiers in Endocrinology, Dec 2020. URL: https://doi.org/10.3389/fendo.2020.601349, doi:10.3389/fendo.2020.601349. This article has 105 citations.
(li2024targetingthefgf19–fgfr4 pages 2-2): Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, and Yongde Luo. Targeting the fgf19–fgfr4 pathway for cholestatic, metabolic, and cancerous diseases. Journal of Internal Medicine, 295:292-312, Jan 2024. URL: https://doi.org/10.1111/joim.13767, doi:10.1111/joim.13767. This article has 66 citations and is from a domain leading peer-reviewed journal.
(katafuchi2022molecularbasisof pages 10-11): Takeshi Katafuchi and Makoto Makishima. Molecular basis of bile acid-fxr-fgf15/19 signaling axis. International Journal of Molecular Sciences, 23:6046, May 2022. URL: https://doi.org/10.3390/ijms23116046, doi:10.3390/ijms23116046. This article has 219 citations.
(wang2022theroleof pages 3-4): Linda X. Wang, Mark R. Frey, and Rohit Kohli. The role of fgf19 and malrd1 in enterohepatic bile acid signaling. Frontiers in Endocrinology, Jan 2022. URL: https://doi.org/10.3389/fendo.2021.799648, doi:10.3389/fendo.2021.799648. This article has 47 citations.
(simbrunner2021reviewarticletherapeutic pages 5-6): Benedikt Simbrunner, Michael Trauner, and Thomas Reiberger. Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis. Alimentary Pharmacology & Therapeutics, 54:1243-1262, Sep 2021. URL: https://doi.org/10.1111/apt.16602, doi:10.1111/apt.16602. This article has 110 citations and is from a highest quality peer-reviewed journal.
(katafuchi2022molecularbasisof pages 11-13): Takeshi Katafuchi and Makoto Makishima. Molecular basis of bile acid-fxr-fgf15/19 signaling axis. International Journal of Molecular Sciences, 23:6046, May 2022. URL: https://doi.org/10.3390/ijms23116046, doi:10.3390/ijms23116046. This article has 219 citations.
(carvalho2024theroleof pages 8-11): Marcela Botelho de Carvalho, Gabriel Machado Chavez Passos Jorge, Luiza Wolf Zanardo, Leticia Miho Hamada, Larissa dos Santos Izabel, Sergio Santoro, and Juliana Magdalon. The role of fgf19 in metabolic regulation: insights from preclinical models to clinical trials. Sep 2024. URL: https://doi.org/10.1152/ajpendo.00156.2024, doi:10.1152/ajpendo.00156.2024. This article has 27 citations.
(carvalho2024theroleof pages 11-14): Marcela Botelho de Carvalho, Gabriel Machado Chavez Passos Jorge, Luiza Wolf Zanardo, Leticia Miho Hamada, Larissa dos Santos Izabel, Sergio Santoro, and Juliana Magdalon. The role of fgf19 in metabolic regulation: insights from preclinical models to clinical trials. Sep 2024. URL: https://doi.org/10.1152/ajpendo.00156.2024, doi:10.1152/ajpendo.00156.2024. This article has 27 citations.
(sadowska2023theroleof pages 4-5): Agata Sadowska, Elżbieta Poniedziałek-Czajkowska, and Radzisław Mierzyński. The role of the fgf19 family in the pathogenesis of gestational diabetes: a narrative review. International Journal of Molecular Sciences, 24:17298, Dec 2023. URL: https://doi.org/10.3390/ijms242417298, doi:10.3390/ijms242417298. This article has 15 citations.
(henriksson2020fgf19andfgf21 pages 6-7): Emma Henriksson and Birgitte Andersen. Fgf19 and fgf21 for the treatment of nash—two sides of the same coin? differential and overlapping effects of fgf19 and fgf21 from mice to human. Frontiers in Endocrinology, Dec 2020. URL: https://doi.org/10.3389/fendo.2020.601349, doi:10.3389/fendo.2020.601349. This article has 105 citations.
(li2024targetingthefgf19–fgfr4 pages 3-3): Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, and Yongde Luo. Targeting the fgf19–fgfr4 pathway for cholestatic, metabolic, and cancerous diseases. Journal of Internal Medicine, 295:292-312, Jan 2024. URL: https://doi.org/10.1111/joim.13767, doi:10.1111/joim.13767. This article has 66 citations and is from a domain leading peer-reviewed journal.
(park2022isoformspecificinhibitionof pages 10-11): Joon Sung Park, Jungyuen Choi, Longxing Cao, Jyotidarsini Mohanty, Yoshihisa Suzuki, Andy Park, David Baker, Joseph Schlessinger, and Sangwon Lee. Isoform-specific inhibition of fgfr signaling achieved by a de-novo-designed mini-protein. Cell reports, 41:111545-111545, Oct 2022. URL: https://doi.org/10.1016/j.celrep.2022.111545, doi:10.1016/j.celrep.2022.111545. This article has 16 citations and is from a highest quality peer-reviewed journal.
(ciaula2022recentadvancesin pages 8-9): Agostino Di Ciaula, Leonilde Bonfrate, Jacek Baj, Mohamad Khalil, Gabriella Garruti, Frans Stellaard, Helen H. Wang, David Q.-H. Wang, and Piero Portincasa. Recent advances in the digestive, metabolic and therapeutic effects of farnesoid x receptor and fibroblast growth factor 19: from cholesterol to bile acid signaling. Nutrients, 14:4950, Nov 2022. URL: https://doi.org/10.3390/nu14234950, doi:10.3390/nu14234950. This article has 74 citations.
(sun2023thefibroblastgrowth pages 1-2): Fuqiang Sun, Panpan Liang, Bo Wang, and Wenbo Liu. The fibroblast growth factor–klotho axis at molecular level. Open Life Sciences, Jan 2023. URL: https://doi.org/10.1515/biol-2022-0655, doi:10.1515/biol-2022-0655. This article has 15 citations and is from a peer-reviewed journal.